Results 41 to 50 of about 5,710 (181)

Evolocumab Added to Statin Is Associated With Intracranial Atherosclerotic Plaque Regression Compared With Statin Alone

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background We aimed to investigate the effects of evolocumab, a proprotein convertase subtilisin/kexin type‐9 inhibitor for intensive lipid‐lowering, on intracranial atherosclerotic stenosis.
Xinzhi Hu, Yiyang Liu, Weizhuang Yuan, Zongmuyu Zhang, Shun Li, Anqi Cheng, Qiuyu Yu, Haoyao Guo, Yinxi Zou, Mingli Li, Caiyan Liu, Yan Xu, Weihai Xu   +12 more
doaj   +1 more source

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)

Lipids in Health and Disease, 2020
Background Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL cholesterol (LDL-C) as ...
Xiang Zhang, Lotte C. A. Stiekema, Erik S. G. Stroes, Albert K. Groen   +3 more
doaj   +1 more source

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol

Frontiers in Physiology, 2021
Background: Several studies have demonstrated that using a higher dose of statin can easily induce liver injury and myopathy. Low-density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor for cardiovascular disease; however ...
Jing Gao, Jing Gao, Jing-Yu Liu, Peng-Ju Lu, Jian-Yong Xiao, Ming-Dong Gao, Chang-Ping Li, Zhuang Cui, Yin Liu, Yin Liu   +9 more
doaj   +1 more source

Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety [PDF]

, 2019
We evaluated the pharmacokinetics, pharmacodynamics, and safety of evolocumab, a fully human monoclonal antibody against proprotein convertase subtilisin kexin type 9 (PCSK9), in an open-label, parallel-design study in participants with normal renal ...
Sreeneeranj Kasichayanula, Scott M. Wasserman, Ogo Egbuna, Kasichayanula, Sreeneeranj, Egbuna, Ogo, Emery, Maurice, Maurice G. Emery, Patrick Hanafin, Gibbs, John, Lee, Edward, Wasserman, Scott, Geoffrey Block, Edward Lee, Hanafin, Patrick, John P. Gibbs, Ransi Somaratne, Hamilton, Lisa, Somaratne, Ransi, Lisa Hamilton, Block, Geoffrey   +19 more
core   +1 more source

Restores Aβ Clearance by Overcoming PCSK9–LRP1 Dysregulation and TRIB3‐Mediated Autophagy Blockade in Alzheimer's Disease

Advanced Science, EarlyView.
PCSK9 upregulation in cerebrovascular endothelial cells and microglia destabilizes the Aβ transporter LRP1, while TRIB3‐associated autophagy blockade further limits intracellular Aβ degradation. A RAP‐modified tea‐polyphenol nanoparticle co‐delivers siPCSK9 and siTRIB3 to restore LRP1‐mediated Aβ efflux and autophagy‐dependent degradation, reducing Aβ ...
Jie Miao, Jing Wang, Yankun Li, Haipei Zhang, Yanli Zhang, Qingnian Li, Bo Xiao, Wenhu Zhou, Junhong Guo   +8 more
wiley   +1 more source

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
Study design and main findings. After 1:1 propensity score matching, 60 885 PCSK9 inhibitor users and 60 885 statin‐only users with ASCVD were compared. Kaplan–Meier curves show 12‐month cumulative event‐free survival for MACE, psychiatric disease, and neurodegenerative disease.
Tianshu Gu, Yang Chen, Nan Zhang, Uazman Alam, Riccardo Proietti, Tong Liu, Kang‐Yin Chen, Gregory Y. H. Lip   +7 more
wiley   +1 more source

Effect of PCSK9 Inhibitor on Contrast-Induced Acute Kidney Injury in Patients with Acute Myocardial Infarction Undergoing Intervention Therapy

Cardiology Research and Practice, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to inhibit pyroptosis and apoptosis, which play important roles in the development and progression of contrast-induced acute kidney injury (CI-AKI).
Yu Ma, Lei Zha, Qi Zhang, Lu Cao, Ru Zhao, Jing Ma, Kai Hou, Yue Pan, Hongliang Cong, Ximing Li   +9 more
doaj   +1 more source

In Silico Clinical Trials in Drug Development: Virtual Patients, Applications, and Regulatory Convergence

Clinical Pharmacology &Therapeutics, EarlyView.
Conventional clinical trials remain the benchmark for evaluating therapeutic safety and efficacy, yet they are constrained by escalating costs, withdrawal over the extended follow‐up periods, recruitment difficulties, ethical limits, and a restricted ability to characterize heterogeneous populations.
Maximilian Balmus, Sheng‐Ya Wang, Edward W. G. Ashton, Rosie K. Barrows, Molly Monks, Yuzhang Ge, Arthur Lefebvre, Steven A. Niederer   +7 more
wiley   +1 more source

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study

Cardiology and Therapy, 2023
Introduction This study characterizes patients receiving evolocumab in clinical practice and assesses treatment effectiveness, safety and persistence outcomes across five countries.
Milan Gupta, Rajvi J. Wani, Khalid Al Faraidy, Jean Bergeron, Eduardo Contreras, Angel Alberto Garcia Peña, G. B. John Mancini, Francisco Padilla, Abel Alberto Pavia Lopez, Kiran Philip, Johnny Wu, Erin S. Mackinnon   +11 more
doaj   +1 more source

Dyslipidaemia, Chronic Kidney Disease and Diabetes Mellitus: A Triple Threat to Cardiovascular Health

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest, Priyanka Majety, Stéphanie B. Mayer, Om P. Ganda   +3 more
wiley   +1 more source